# BridgeBio Oncology Therapeutics, Inc.: overview BBOT · Nasdaq · CIK 1869105 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/bbot.md) · [Financials](/companies/bbot/financials.md) · [Filings](/companies/bbot/filings.md) · [Insiders](/companies/bbot/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1562.18)](/filings/0001193125-25-277834.md) | not reported | [(54.23)](/filings/0001193125-26-219829.md) | [(566.46)](/filings/0001193125-26-344661.md) | [(1.03)](/filings/0001193125-25-277834.md) | not reported | [(526.11)](/filings/0001193125-26-219829.md) | [(705.20)](/filings/0001193125-26-344661.md) | | Free cash flow | $m | not reported | [(15.0) d](/filings/0001193125-26-094112.md) | [(19.8)](/filings/0001193125-26-219829.md) | [(23.5) d](/filings/0001193125-26-344661.md) | [(28.9) d](/filings/0001193125-25-277834.md) | [(42.3) d](/filings/0001193125-26-094112.md) | [(35.9)](/filings/0001193125-26-219829.md) | [(44.4) d](/filings/0001193125-26-344661.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | [(5756.41)](/filings/0001193125-26-094112.md) | [(4.30)](/filings/0001193125-26-094112.md) | | Free cash flow | $m | not reported | [(55.1)](/filings/0001193125-26-094112.md) | [(115)](/filings/0001193125-26-094112.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bbot/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Cormorant Asset Management, LP](/funds/1583977.md) | 2026-06-30 | $136.2m | 17,878,594 | | Unchanged | | [DEERFIELD MANAGEMENT COMPANY, L.P.](/funds/1009258.md) | 2026-06-30 | $37.2m | 4,885,446 | | Unchanged | | [Omega Fund Management, LLC](/funds/1637359.md) | 2026-06-30 | $25.1m | 3,289,661 | | Unchanged | | [EcoR1 Capital, LLC](/funds/1587114.md) | 2026-06-30 | $21.5m | 2,823,126 | | Unchanged | | [Alphabet Inc.](/funds/1652044.md) | 2026-06-30 | $21.5m | 2,823,126 | | Unchanged | | [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $21.3m | 2,789,302 | | Reduced −29,046 | | [ENAVATE SCIENCES GP, LLC](/funds/1953107.md) | 2026-06-30 | $20.0m | 2,626,946 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $19.9m | 2,617,827 | | Added +89,065 | | [NOVO HOLDINGS A/S](/funds/1388325.md) | 2026-06-30 | $17.1m | 2,250,000 | | Added +64,077 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $16.4m | 2,154,040 | | Added +65,743 | ## Recent filings [All 181 filings](/companies/bbot/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-08 | 20:19 ET | [8-K](/filings/0001193125-26-385225.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-385225 | | 2026-08-11 | 20:12 ET | [10-Q](/filings/0001193125-26-344661.md) | Quarterly report, period 2026-06-30 | 0001193125-26-344661 | | 2026-08-11 | 20:07 ET | [8-K](/filings/0001193125-26-344608.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-344608 | | 2026-07-06 | 20:37 ET | [SCHEDULE 13D/A](/filings/0001213900-26-075546.md) | Ownership report, active investor, amended | 0001213900-26-075546 | | 2026-06-22 | 20:05 ET | [8-K](/filings/0001193125-26-277513.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001193125-26-277513 | | 2026-05-12 | 21:11 ET | [10-Q](/filings/0001193125-26-219829.md) | Quarterly report, period 2026-03-31 | 0001193125-26-219829 | | 2026-05-12 | 21:07 ET | [8-K](/filings/0001193125-26-219801.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-219801 | | 2026-04-29 | 20:05 ET | [8-K](/filings/0001193125-26-191512.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-191512 | | 2026-04-28 | 20:06 ET | [DEF 14A](/filings/0001193125-26-186944.md) | Proxy statement, period 2026-06-16 | 0001193125-26-186944 | | 2026-04-23 | 21:31 ET | [8-K](/filings/0001193125-26-170888.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-170888 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-094112.md), filed Mar 5, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1869105 - Tickers: BBOT - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.